Notably, RNK05028 displays tumor-targeted pharmacokinetics and prolonged specifical degradation of BRD4 in vivo, which demonstrated the potential of the novel TPD strategy.536 In 2023, another multi-specific molecule recruiting HSP90, HEMTAC 26, was also designed for selective degradation of CDK4/6 with DC50 of 26/19 nM (Table 3). The gene discussed is CDK4; the disease is neoplasm.